Wendy Tate, PhD

In my current role at Nimblify, I collaborate with institutions and other clinical research stakeholders to develop and validate meaningful and quality metrics regarding various aspects of clinical trial operations.
Status: 
Alumni
Degree: 
PhD
Program: 
Pharmaceutical Sciences
Track: 
Pharmaceutical Economics, Policy and Outcome
Dissertation Title: 
Evaluation of Efficiency in the Activation and Accrual of Interventional Clinical Trials as Cancer Centers
Year Enrolled: 
2011
Phone: 
520-626-7265
Education: 
MS, Applied Biosciences (2005) The University of Arizona, Tucson, AZ BS, Molecular and Cellular Biology (2001) The University of Arizona, Tucson, AZ
Research Interests: 
  • Pharmaceutical regulations and ethics
  • Research Compliance and Policy
  • Cancer
Honors and Achievements: 
1. Graduate Track Awards: Academic Excellence, 2014-15.
2. The Arizona Chapter of the Healthcare Information and Management Systems Society (AzHIMSS) Award, 2014-15.
Publications: 

1. Tate WR, Skrepnek, GH. Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST): Patient Reported Outcome or Mathematical Model? A Systematic Review in Cancer. Psycho-Oncology; 24(3):253-61, 2015.​
2. Skrepnek GH, Tate WR. Clinical and Economic Characteristics of Richter’s Syndrome in Chronic Lymphocytic Leukemia Inpatient Cases within the United States, 2001-2010. Leuk Lymphoma, Apr;55(4):834-840, 2014.
3. Baker AF, Koh MY, Williams R, James B, Wang H, Tate WR, Gallegos A, Von Hoff DD, Han H, Powis G. Identification of Thioredoxin-Interacting Protein-1 (TXNIP) as a HIF-1α Induced Gene in Pancreatic Cancer. Pancreas; 2008;36:2.
4. Baker AF, Landowski T, Dorr R, Tate WR, Gard JM, Tavenner BE, Dragovich T, Coon A, Powis G. The Antitumor Agent Imexon Activates Antioxidant Gene Expression: Evidence for an Oxidative Stress Response. Clinical Cancer Research, Jun 1;13(11):3388-94, 2007.
5. Baker AF, Bellamy W, Tate WR, Bair W, Heaton R, List A. Suppressor of Cytokine Signaling-3 (SOCS-3) is Over-Expressed in Erythroid Precursors of Myelodysplastic Syndrome. Leukemia, Sep;20(9):1620-1, 2006.
6. Baker AF, Dragovich T, Tate WR, Ramanathan R, Roe D, Hsu C-H, Kirkpatrick DL, Powis G. The Thioredoxin-1 Inhibitor PX-12 (1-Methylpropyl 2-Imidazolyl Disulfide) Decreases Thioredoxin-1 and VEGF Levels in Patient Plasma. The Journal of Laboratory and Clinical Medicine, Feb;147(2):83-90, 2005.
7. Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham R, Kirkpatrick L and Powis G. The Phosphoinositide-3-Kinase Inhibitor PX-866 Overcomes the Resistance of A-549 Human Non Small Cell Lung Cancer Xenografts to the EGF Receptor Inhibitor Gefitinib and a Decreased Blood Tolerance is Reversed by the PPARγ Ligand Pioglitazone. Molecular Cancer Therapeutics, Sep;4(9):1349-57, 2005.
8. Jordan BF, Runquist M, Raghunand N, Gillies RJ, Tate WR, Powis G and Baker AF. The Thioredoxin-1 Inhibitor PX-12 Decreases Vascular Permeability in Tumor Xenografts Monitored by Dynamic Contrast Enhanced MRI. Clinical Cancer Research, Jan 15;11(2 Pt1):529-36, 2005.
9. Tate WR, Skrepnek GH, "Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST): Patient Reported Outcome or Mathematical Model? A Systematic Review in Cancer." Psycho-Oncology. 2015 Mar;24(3):253-61.

 

Alumna or Alumnus: 
Alumna
Alumni Title/Position/Employer: 
Director, Data Analytics at Nimblify, Inc
Career Type: 
Industry